PYRIDOSTIGMINE BROMIDE Drug Patent Profile

Which patents cover Pyridostigmine Bromide, and when can generic versions of Pyridostigmine Bromide launch?

Pyridostigmine Bromide is a drug marketed by Amneal, Milla Pharms, MSN, Novitium Pharma, Rising, Alvogen, Impax Labs Inc, Ani Pharms, Impax Labs, MLV, Solvay, Us Army, and Zydus Pharms. and is included in sixteen NDAs. There are nine patents protecting this drug.

This drug has nineteen patent family members in seven countries.

The generic ingredient in PYRIDOSTIGMINE BROMIDE is pyridostigmine bromide. There are eleven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pyridostigmine Bromide

A generic version of PYRIDOSTIGMINE BROMIDE was approved as pyridostigmine bromide by IMPAX LABS on April 24^th, 2003.

Summary for PYRIDOSTIGMINE BROMIDE

International Patents:	19
US Patents:	9
Applicants:	13
NDAs:	16

US Patents and Regulatory Information for PYRIDOSTIGMINE BROMIDE

PYRIDOSTIGMINE BROMIDE is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	SYRUP;ORAL	212702-001	Jan 10, 2020	AA	RX	No	No
Ani Pharms	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET;ORAL	040512-002	Jul 20, 2005		DISCN	No	No
Mlv	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET;ORAL	211181-001	Jul 20, 2018	AB	RX	No	No
Amneal	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET, EXTENDED RELEASE;ORAL	217604-001	Oct 4, 2024		DISCN	No	No			Y
Novitium Pharma	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	SYRUP;ORAL	211694-001	Mar 8, 2019	AA	RX	No	No
Amneal	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET, EXTENDED RELEASE;ORAL	217604-001	Oct 4, 2024		DISCN	No	No			Y
Impax Labs	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET;ORAL	040502-002	Jun 28, 2022	AB	RX	No	No

International Patents for PYRIDOSTIGMINE BROMIDE

See the table below for patents covering PYRIDOSTIGMINE BROMIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3061382	COMPOSITIONS A LIBERATION PROLONGEE COMPRENANT DE LA PYRIDOSTIGMINE (EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE)
China	110996922	用于持续药物递送的胃滞留剂型 (GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY)
Japan	7048770
European Patent Office	3609472	COMPOSITIONS À LIBÉRATION PROLONGÉE COMPRENANT DE LA PYRIDOSTIGMINE (EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE)
European Patent Office	3648747	FORMES POSOLOGIQUES À RÉTENTION GASTRIQUE DESTINÉES À UNE ADMINISTRATION DE MÉDICAMENT PROLONGÉE (GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY)
Canada	3061382
European Patent Office	3609472

Investment Scenario and Fundamentals Analysis for Pyridostigmine Bromide

Last updated: February 20, 2026

What Is Pyridostigmine Bromide?

Pyridostigmine bromide is a cholinesterase inhibitor primarily used to treat myasthenia gravis, a neuromuscular disorder. It enhances communication between nerves and muscles by inhibiting acetylcholinesterase. Approved in multiple countries, including the U.S. by the FDA and in Europe, it has a well-established clinical profile.

Market Overview and Demand Drivers

Prevalence and Market Size

• Myasthenia gravis prevalence: Estimated at 20-300 cases per million globally.

• Market value (2022): Approximate global sales of pyridostigmine bromide approached USD 200 million, with steady growth projected at 3-5% annually.

• Key markets: U.S., Europe, Japan account for over 70% of sales.

Key Demand Drivers

• Increase in diagnosed cases due to improved detection.
• Aging populations in developed countries raising prevalence.
• Ongoing off-label uses and investigational applications, such as in treatment protocols for Raynaud's phenomenon and certain neuromuscular conditions.

Competitive Landscape

• Major manufacturers: EMD Serono (Merck KGaA), Teva Pharmaceutical Industries, Mylan.
• Generic dominance: The patent expiration of branded formulations led to a crowded generics market, driving price competition.
• Patent status: No recent patents; manufacturing is primarily based on established processes.

Regulatory and Reimbursement Environment

• Approved in the U.S. via NDA, with a "highly generic" status.
• Reimbursed broadly across healthcare systems, with variations based on healthcare policies.
• Emerging focus on production quality standards due to concerns over counterfeit or sub-standard generics.

Supply Chain and Manufacturing Considerations

• Synthetic process involves synthesis of pyridine derivatives, with established routes from relatively inexpensive raw materials.
• Manufacturing has low complexity relative to biologics.
• Supply risks are minimal but include raw material shortages and regulatory compliance.

Investment Considerations

Opportunities

• Rising prevalence in aging populations increases demand.
• The global generics market for neuromuscular drugs is expanding, benefiting established players.
• Potential for value-added formulations or combination therapies.

Risks

• Market saturation due to numerous generic manufacturers.
• Price erosion driven by intense competition.
• Regulatory risks linked to manufacturing standards.
• Limited innovation as the compound is well-established.

Financial Metrics

Indicator	Data (2022)	Comments
Market size	USD 200 million	Moderate growth rate
Major players' market share	60% combined	Dominant firms control the majority
Price trend	Downward over past 5 years	Due to generic competition
R&D investment in new formulations	Minimal	Focus remains on production and quality

Strategic Outlook

• For existing companies, focus on cost-efficient manufacturing and quality assurance.
• Opportunities exist in expanding into emerging markets where diagnosis and treatment coverage are increasing.
• Companies with capabilities in formulation extensions or combination therapies might gain competitive edge.

Key Challenges

• Market saturation limits pricing power.
• Regulatory compliance costs increase with stricter standards.
• Limited room for innovation due to the compound's mature status.

Conclusion

Pyridostigmine bromide presents a low-growth but stable investment opportunity driven by steady demand from neuromuscular disorder markets. The landscape favors companies with efficient manufacturing, strict quality controls, and access to emerging markets. Investment prospects hinge on market share retention amid price pressures and regulatory stability.

Key Takeaways

• Market size remains stable but faces pressure from generic competition and price erosion.
• Growth is driven primarily by demographic trends and diagnosis rates.
• Limited innovation opportunities due to the mature status of the drug.
• Competitive advantage relies on manufacturing efficiency and quality standards.
• Emerging markets may offer incremental growth.

FAQs

Q1: Is the patent expiration of pyridostigmine bromide a significant concern?

A1: The expiration led to generic proliferation, intensifying competition and reducing prices, which affects margins but sustains steady demand.

Q2: Are there ongoing clinical trials for new indications?

A2: Limited research exists; most focus on expanding existing indications or optimizing formulations rather than new therapeutic uses.

Q3: How does regulatory environment impact investment?

A3: Stringent manufacturing and quality standards can increase costs but also create barriers against new entrants, benefiting established firms.

Q4: What are the key growth markets for pyridostigmine bromide?

A4: Emerging markets in Asia, Latin America, and Africa are expanding access, offering potential for growth.

Q5: Can innovation impact the future market for pyridostigmine bromide?

A5: Due to its mature status, significant innovation is unlikely. Incremental improvements or combination therapies may provide modest advantages.

---

References

[1] IMS Health. (2022). Global Neuromuscular Disease Market Report.

[2] U.S. Food and Drug Administration. (2023). Drug Approvals and Regulatory Updates.

[3] IQVIA. (2022). Pharmaceutical Market Trends Analysis.

[4] European Medicines Agency. (2023). Generic Drug Policy and Market Data.

[5] Williams, L. (2021). Generic Drug Competition and Price Trends. Journal of Pharmaceutical Economics.